COMPARISON OF LIPID LOWERING EFFECTS OF ROSUVASTATIN AND ATORVASTATIN IN TYPE 2 DIABETIC PATIENTS WITH PRIMARY HYPERLIPIDEMIA

Objective: To evaluate & compare the mean change in fasting serum total cholesterol and LDL-C levels from baseline, after 12 weeks of oral treatment with oral Rosuvastatin and with Atorvastatin in type 2 diabetic patients with primary hyperlipidemia. Study Design: Cross sectional comparative...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Safina Shabbir, Zill -e- Humayun, Muhammad Javad Yousaf, Muhammad Adnan Manzar, Shabana Mushtaq, Maria Yousaf
Formato:	article
Lenguaje:	EN
Publicado:	Army Medical College Rawalpindi 2020
Materias:	atorvastatin diabetes mellitus hyperlipidemia rosuvastatin Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/d8f0d65f3f354ee8a7f84f9724a06ee8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d8f0d65f3f354ee8a7f84f9724a06ee8
record_format	dspace
spelling	oai:doaj.org-article:d8f0d65f3f354ee8a7f84f9724a06ee82021-12-02T14:57:42ZCOMPARISON OF LIPID LOWERING EFFECTS OF ROSUVASTATIN AND ATORVASTATIN IN TYPE 2 DIABETIC PATIENTS WITH PRIMARY HYPERLIPIDEMIA0030-96482411-8842https://doaj.org/article/d8f0d65f3f354ee8a7f84f9724a06ee82020-12-01T00:00:00Zhttps://pafmj.org/index.php/PAFMJ/article/view/5866https://doaj.org/toc/0030-9648https://doaj.org/toc/2411-8842Objective: To evaluate & compare the mean change in fasting serum total cholesterol and LDL-C levels from baseline, after 12 weeks of oral treatment with oral Rosuvastatin and with Atorvastatin in type 2 diabetic patients with primary hyperlipidemia. Study Design: Cross sectional comparative study. Place and Duration of Study: The present study was conducted in the Medicine Department, Pakistan Naval Ship, Shifa Hospital, Karachi, from Mar to Sep 2016. Methodology: The sample was collected by non- probability convenient sampling. The total of 114 DM type 2 patients were randomly divided into two equal groups. Group A was given Rosuvastatin whereas group B was given Atorvastatin orally daily for 12 weeks along with oral treatment for diabetes. After 12 weeks, Fasting Serum Total Cholesterol and Serum LDL-C were estimated, and noted as final levels. Results: There was greater reduction in terms of mean change in serum total cholesterol levels and low-density lipoprotein – cholesterol (LDL-C) levels with Rosuvastatin as compared to Atorvastatin in type 2 diabetic patients with hyperlipidemia. Conclusion: Rosuvastatin can significantly improve lipid profile as compared to Atorvastatin in type 2 diabetic patients with hyperlipidemia.Safina ShabbirZill -e- HumayunMuhammad Javad YousafMuhammad Adnan ManzarShabana MushtaqMaria YousafArmy Medical College Rawalpindiarticleatorvastatindiabetes mellitushyperlipidemiarosuvastatinMedicineRMedicine (General)R5-920ENPakistan Armed Forces Medical Journal, Vol 70, Iss 6, Pp 1671-1675 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	atorvastatin diabetes mellitus hyperlipidemia rosuvastatin Medicine R Medicine (General) R5-920
spellingShingle	atorvastatin diabetes mellitus hyperlipidemia rosuvastatin Medicine R Medicine (General) R5-920 Safina Shabbir Zill -e- Humayun Muhammad Javad Yousaf Muhammad Adnan Manzar Shabana Mushtaq Maria Yousaf COMPARISON OF LIPID LOWERING EFFECTS OF ROSUVASTATIN AND ATORVASTATIN IN TYPE 2 DIABETIC PATIENTS WITH PRIMARY HYPERLIPIDEMIA
description	Objective: To evaluate & compare the mean change in fasting serum total cholesterol and LDL-C levels from baseline, after 12 weeks of oral treatment with oral Rosuvastatin and with Atorvastatin in type 2 diabetic patients with primary hyperlipidemia. Study Design: Cross sectional comparative study. Place and Duration of Study: The present study was conducted in the Medicine Department, Pakistan Naval Ship, Shifa Hospital, Karachi, from Mar to Sep 2016. Methodology: The sample was collected by non- probability convenient sampling. The total of 114 DM type 2 patients were randomly divided into two equal groups. Group A was given Rosuvastatin whereas group B was given Atorvastatin orally daily for 12 weeks along with oral treatment for diabetes. After 12 weeks, Fasting Serum Total Cholesterol and Serum LDL-C were estimated, and noted as final levels. Results: There was greater reduction in terms of mean change in serum total cholesterol levels and low-density lipoprotein – cholesterol (LDL-C) levels with Rosuvastatin as compared to Atorvastatin in type 2 diabetic patients with hyperlipidemia. Conclusion: Rosuvastatin can significantly improve lipid profile as compared to Atorvastatin in type 2 diabetic patients with hyperlipidemia.
format	article
author	Safina Shabbir Zill -e- Humayun Muhammad Javad Yousaf Muhammad Adnan Manzar Shabana Mushtaq Maria Yousaf
author_facet	Safina Shabbir Zill -e- Humayun Muhammad Javad Yousaf Muhammad Adnan Manzar Shabana Mushtaq Maria Yousaf
author_sort	Safina Shabbir
title	COMPARISON OF LIPID LOWERING EFFECTS OF ROSUVASTATIN AND ATORVASTATIN IN TYPE 2 DIABETIC PATIENTS WITH PRIMARY HYPERLIPIDEMIA
title_short	COMPARISON OF LIPID LOWERING EFFECTS OF ROSUVASTATIN AND ATORVASTATIN IN TYPE 2 DIABETIC PATIENTS WITH PRIMARY HYPERLIPIDEMIA
title_full	COMPARISON OF LIPID LOWERING EFFECTS OF ROSUVASTATIN AND ATORVASTATIN IN TYPE 2 DIABETIC PATIENTS WITH PRIMARY HYPERLIPIDEMIA
title_fullStr	COMPARISON OF LIPID LOWERING EFFECTS OF ROSUVASTATIN AND ATORVASTATIN IN TYPE 2 DIABETIC PATIENTS WITH PRIMARY HYPERLIPIDEMIA
title_full_unstemmed	COMPARISON OF LIPID LOWERING EFFECTS OF ROSUVASTATIN AND ATORVASTATIN IN TYPE 2 DIABETIC PATIENTS WITH PRIMARY HYPERLIPIDEMIA
title_sort	comparison of lipid lowering effects of rosuvastatin and atorvastatin in type 2 diabetic patients with primary hyperlipidemia
publisher	Army Medical College Rawalpindi
publishDate	2020
url	https://doaj.org/article/d8f0d65f3f354ee8a7f84f9724a06ee8
work_keys_str_mv	AT safinashabbir comparisonoflipidloweringeffectsofrosuvastatinandatorvastatinintype2diabeticpatientswithprimaryhyperlipidemia AT zillehumayun comparisonoflipidloweringeffectsofrosuvastatinandatorvastatinintype2diabeticpatientswithprimaryhyperlipidemia AT muhammadjavadyousaf comparisonoflipidloweringeffectsofrosuvastatinandatorvastatinintype2diabeticpatientswithprimaryhyperlipidemia AT muhammadadnanmanzar comparisonoflipidloweringeffectsofrosuvastatinandatorvastatinintype2diabeticpatientswithprimaryhyperlipidemia AT shabanamushtaq comparisonoflipidloweringeffectsofrosuvastatinandatorvastatinintype2diabeticpatientswithprimaryhyperlipidemia AT mariayousaf comparisonoflipidloweringeffectsofrosuvastatinandatorvastatinintype2diabeticpatientswithprimaryhyperlipidemia
_version_	1718389353965682688

COMPARISON OF LIPID LOWERING EFFECTS OF ROSUVASTATIN AND ATORVASTATIN IN TYPE 2 DIABETIC PATIENTS WITH PRIMARY HYPERLIPIDEMIA

Ejemplares similares